Lexaria reports enhanced brain delivery of semaglutide using DehydraTECH
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St futures rise on Mideast deal hopes; SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain
September 19, 2025 11:20 AM EDTEnhanced Brain Biodistribution of GLP-1 Drugs May Be Related to Improvements in Safety and Efficacy
KELOWNA, BC / ACCESS Newswire / September 19, 2025 / Lexaria Bioscience Corp. (Nasdaq: LEXX)(Nasdaq: LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce successful results from its fluorescently tagged semaglutide ("FTS") rodent biodistribution study (the "Study").
The main goal of the Study was to determine whether the... More
